Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice.

阅读:4
作者:Tabor G Travis, Litvinchuk Alexandra, Chen Yun, Allison Austin, Sun Elizabeth W, van Lengerich Bettina, Davis Sonnet S, West Elizabeth, Schlachetzki Johannes C M, Zeng Carisa, Hu Hao, Lin Peter B, Sharma Prabal, Chen Xiaoying, Parhizkar Samira, Song Sihui, Bao Xin, Senthil Lakshita, Iyer Abhirami K, You Shih Feng, Serrano Javier Remolina, Manis Melissa, Franke Emily, Cashikar Anil G, Yuede Carla M, Suh Jung H, Karch Celeste M, Folick Andrew, Koliwad Suneil K, Farese Robert V Jr, Walther Tobias, Huang Eric J, Artyomov Maxim, Glass Christopher K, Di Paolo Gilbert, Ulrich Jason D, Holtzman David M
Brain myeloid cells accumulate neutral lipids in multiple human neurodegenerative disorders and relevant mouse models. These lipids are often assumed to be contained in lipid droplets (LDs). While studies have been performed in cell culture and Drosophila models to characterize glial LDs, the roles of microglial LD biogenesis in mammalian tauopathy are unclear. To address this issue, we induced the deletion of diacylglycerol acyltransferases (DGATs) 1 and 2, enzymes critical for LD formation, from microglia in the PS19 mouse model of tauopathy. Microglial DGAT double knockout (KO) exacerbated neurodegeneration and increased the abundance of brain cholesteryl esters in male PS19 mice. Myeloid cell lipid accumulations appeared to largely localize to endosomes/lysosomes, not LDs, at baseline and were exacerbated upon DGAT KO. Our results suggest that microglial DGAT-dependent TAG/LD biogenesis is adaptive in advanced tauopathy. Most lipid accumulation in brain myeloid cells does not appear to correspond to LDs in this tauopathy model, which has implications for the development of lipid-modulating therapies for neurodegenerative diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。